Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If it drops today to $3.05 I'm buying more.
Agree, great buy and hold and just see what the future holds. Best to you.
Potential is huge on ACRX especially if it becomes the SOC...
No doubt this is a good long term hold..
Nice to see this trading well above and holding $3. Best to all here. Buy the dips.
nothing was up we were down. makes no sense to me. fda approval and all else going for this company other than a bunch of usles democrats that keep yelling to drop RX prices while someone lines the politicians pockets for doing so.
.36 swing today, not sure what's up, but I'll take the green. Dip n' rip?
Yeah just normal trading day after consecutive up days
I totally agree..
I think the PPS has everything to do with financials and growth, not conferences unless there is big buy news.
looks like Oppenheimer conference wasn't a big deal for ACRX. Price actually went down after start of presentation.
Guess attendees weren't that excited about ACRX chances with new drug launch. May be in a show me stance due to Opiod negative publicity.
ACRX $3.475 Presenting in about 3+ hrs. There will be a small window for listeners to buy stock after presentation or early tomorrow. Hopefully positive response from knowledgeable attendees.
Oppenheimer 29th Annual Healthcare Conference
Date: Wednesday, March 20, 2019
Location: Westin Grand Central, New York, NY
Presentation Time: 2:45 pm ET (11:45 a.m. PT)
The conference presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
Except today but can not complain tho..
For sure keep it growing
I'm perfectly happy with 5 cents a day green.
We have a creeper here folks scratching and clawing its way back up.
Sure it has it's positive days ahead but until it doubles it will be all over the place on the slightest rumor bad or good mostly false hopes until hard numbers come in. The conference call showed even if they are on track they are not going to cause any reason for excitement, sometimes I wonder if they are running a private company instead of the public one it is supposed to be
Yes, for me this is a no brainer buy and hold long term. I keep adding on the little dips. If it goes down more, I'll add more. Agree to the assessment of at least $5 by end of year.
Agree on the potential here. Great upside. I am buying and holding personally here.
I did just that added 1k shares @ 3.25
By the end of this year ACRX will prolly be at $5ish or better..
Going to be volatile today. Mixed results and AH market up to $4 ish and down to $3.50 ish...might see same in-betweens here. Pre-market seems positive.
AcelRx Pharmaceuticals Q4 EPS $(0.18) Beats $(0.20) Estimate, Sales $613K Miss $1.51M Estimate
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $613 thousand which missed the analyst consensus estimate of $1.51 million by 59.40 percent. This is a 17.16 percent decrease over sales of $740 thousand the same period last year.
We will see a drop in price just to spook the shareholders to sell their shares for cheap...I say let's take advantage of any dip and add more shares.
This is a great company with an excellent set of product and above all excellent leadership.
GLTA.
Crawford.
Agree. I think it was a success. This gives us a chance to add more shares for later this year. Best to all here
well, I thought press conference was a success. Early indications are good as company is moving up plans to hire the next 25 account managers to Q3 instead of Q4. As I suspected, hospitals are big institutions with committees to approve/decline new drugs. This is going to take some time for actual sales and new procedures to be implemented.
However ACRX did up guidance from 100 to 125 formulary wins at hospitals over the rest of the year. They have already shipped initial shipments to wholesalers but until they get the formulary wins and the hospitals are ready to train staff on new procedures, actual sales will wait.
Even then, it will take some time for hospitals to get initial supplies, install their procedures and then use Dsuvia. Actual success of the drug will depend on actual usage AND reorder amounts and frequency of reorders.
We still have several quarters before we will know if Dsuvia is a commercial success. Initial indications look good to me and ACRX is not hyping but being quite practical and conservative. I will hold until more actual results come in over the next several months. Looks like premarket there will be a modest drop in the stock price.
Good Luck to you mate. All the best. Hope everyone makes money and they do this drug right. Win for everyone.
no, I'm a pretty recent buyer so going to hold for the ride. Hope it's long and steep.
So are you selling before close? I have a profit, not looking to sell - but I could easily double my shares if I sold and rebuy under $3...now where did I put that crystal ball...?
Won't have long to wait. Conference will begin in less than two hours.
I don't expect $2 but even if it happens, actual sales results over the next year will tell the tale.
I think if the news isn't anything earth shaking there will be a short term sell-off down to $3 at least. People are expecting something in the form of sales, orders, or projected dates. If they just say there is a cash valuation and no orders --- $2.
I doubt the news conference will be earth shaking. They will repeat their sales campaign blueprint and MAY report some initial sales backlog. I hope they give us a realistic timeframe when they will report actual sales and progress. This could take several weeks before there are any significant sales to report.
Hopefully the hospitals will get feedback from the field that turnaround has been improved due to the drug and patients are going home in a timely manner, happy with the speed of their treatment.
Most people who have to use the emergency room may be grateful for the resolution of their injury/illness but few would say it was quick.
Sell or hold before close? I'm holding.
Read last few posts. FDA director resigned.
Woah! What happened there? Anyone got a clue how it dipped so quickly? Did someone put in a 'market' order and the MM had a field day?
Oh boy! Daylight robbery by the market makers and a classic moved by them :)
I don't know why people fall for it tho I guess only those who've done little DD before getting in the stock..
thanks, coming back pretty quickly but still a little underwater for the day. With Trump appointing a new FDA chair, I can't see approvals going down. Besides ACRX already has their approval so I don't see any big issue.
Bought as much as I could afford on the huge dip.
No FDA chair is leaving spooking drug stocks
big volume, big drop. Someone got nervous about tomorrow OR got some inside info.
Great to see the $4's going. Hoping to be back over that soon. Best to all here.
Yup gotta love it.. Follow the trend and the trend is your friend :)
GO ACRX! keep them green coming..
Lots of form 4s coming thru More insider transactions
Exactly Bob huge potential on ACRX ..
Nice close..
the volume today and the steady nature of the uptrend convinces me that institutional money believes that Dsuvia will succeed. Over 4 million shares traded today or over $15 million. There is probably a decent number of retail buyers but I'm betting that's mutual funds and hedge funds buying before actual sales boost ACRX's stock into double digits.
I expect the runup to continue into Thursday news conference. We have close to $100 million in cash to conduct a proper sales campaign. We have experienced sales staff that have done similar campaigns for small cap companies.
After some readings over the weekend and took position today ACRX could get EXEL-like in the making when I got in on EXEL at $3something/share way back then but sold too soon..Atleast that's what my instinct tells me
Hard to believe credit suisse would put its rating out if there issues at acrx, got to believe good news coming Thursday
With the March 7 event, a lot more upside than down. Only thing that would send this south is a delay in Q1 order/delivery.
Agree the potential is huge here with this one. Great to see all the green this week. More coming.
I love this stock. I'm going to buy more Monday. I think this stock's going to ramp through $10 a share. Rather quickly.
4th Qtr Conference Call 7 March. Would not be surprised if they mentioned during the outlook guidance.
Followers
|
94
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1425
|
Created
|
02/13/11
|
Type
|
Free
|
Moderators |
Market Cap: $108 Million
Cash: $72 Million
Price: $2.40
Shares Out: 45.3 Million
Upcoming Major Milestones
Zalviso Phase 3 Results in July 2017
DSUVIA PDUFA Date October 12, 2017
Zalsviso NDA Resubmission in Q4 2017
DSUVIA CHMP Opinion in 1H 2018 (EU Approval )
Presentation June 2017
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjczNjExfENoaWxkSUQ9MzgxNTY1fFR5cGU9MQ==&t=1
Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target
https://finance.yahoo.com/news/jefferies-sees-strong-upside-acelrx-145225845.html
Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)...
https://insiderfinancial.com/biotech-catalyst-play-acelrx-pharmaceuticals-inc-nasdaqacrx
While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.
https://finviz.com/quote.ashx?t=acrx&ty=c&ta=1&p=d
Shs Outstand | 119.10M |
Shs Float | 116.83M |
Short Float | 13.47% |
Insider Own | 2.00% |
Inst Own | 34.80% |
Inst Trans | 43.60% |
Inst Trans | 43.60% |
ROE | 66.50% |
ROI | 120.80% |
Employees | 54 |
Forward P/E | 16.13 |
Recom | 1.70 |
52W Range | 1.01 - 2.94 |
minor resistance $1.70 [-chart]finviz.com/chart.ashx?t=acrx&ty=c&ta=1&p=d&s=l[/chart]
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |